502688448 02/20/2014

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2735053

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	NOTICE AND CONFIRMATION OF GRANT OF SECURITY INTEREST IN PATENTS-FIRST LIEN	

CONVEYING PARTY DATA

Name	Execution Date
PHARMEDIUM SERVICES, LLC	01/28/2014

RECEIVING PARTY DATA

Name:	JPMORGAN CHASE BANK, N.A.
Street Address:	383 MADISON AVENUE
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10179

PROPERTY NUMBERS Total: 41

Property Type	Number
Application Number:	13269874
Application Number:	13443600
Application Number:	13938937
Patent Number:	8597271
Application Number:	14093765
Application Number:	13743981
Patent Number:	D687894
Patent Number:	7918830
Patent Number:	8382717
Application Number:	13759785
Patent Number:	D588200
Patent Number:	D595361
Patent Number:	D602534
Patent Number:	D593613
	PATENT

Patent Number:	D607941
Patent Number:	D614703
Patent Number:	D605230
Patent Number:	D605229
Patent Number:	D605228
Patent Number:	D597608
Patent Number:	D624595
Patent Number:	D621880
Patent Number:	D624596
Patent Number:	D621879
Patent Number:	D633151
Patent Number:	D634368
Patent Number:	D639862
Patent Number:	D639863
Patent Number:	D639861
Patent Number:	D634367
Patent Number:	D641421
Patent Number:	D643468
Patent Number:	D641422
Patent Number:	D634369
Patent Number:	D645094
Patent Number:	D643469
Patent Number:	D643470
Patent Number:	D649196
Patent Number:	D643471
Patent Number:	D643472
Application Number:	61873623

CORRESPONDENCE DATA

 Fax Number:
 (212)455-2502

 Phone:
 (212) 455-3605

 Email:
 ksolomon@stblaw.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: GENEVIEVE DORMENT, ESQ.

Address Line 1: SIMPSON THACHER & BARTLETT LLP

Address Line 2: 425 LEXINGTON AVENUE
Address Line 4: NEW YORK, NEW YORK 10017

	509265/1819		
NAME OF SUBMITTER:	GENEVIEVE DORMENT		
Signature:	/gd/		
Date:	02/20/2014		
Total Attachments: 8			

source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page1.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page2.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page3.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page4.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page5.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page6.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page7.tif source=6 2 First Lien Notice and Confirmation of Grant of Security Interest in Patents#page8.tif

NOTICE AND CONFIRMATION OF GRANT OF SECURITY INTEREST IN PATENTS

NOTICE AND CONFIRMATION OF GRANT OF SECURITY INTEREST IN PATENTS (the "Agreement"), dated as of January 28, 2014, made by PHARMEDIUM SERVICES, LLC, a Delaware limited liability company having a principal place of business at Two Conway Park, 150 North Field Drive, Suite 350, Lake Forest, Illinois 60045 (the "Grantor"), in favor of JPMORGAN CHASE BANK, N.A., having a principal place of business at 383 Madison Avenue, New York, New York 10179 (in such capacity, the "Collateral Agent"), as administrative agent for the banks and other financial institutions (collectively, the "Lenders") from time to time parties to the First Lien Credit Agreement (as defined below) and as collateral agent for the Secured Parties (as defined in the First Lien Credit Agreement). Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided or provided by reference in the First Lien Credit Agreement and the First Lien Guarantee and Collateral Agreement (as defined below), as applicable.

WHEREAS, pursuant to that certain First Lien Credit Agreement, dated as of the date hereof (as amended, supplemented or otherwise modified from time to time, the "First Lien Credit Agreement"), among PharMEDium Healthcare Corporation, a Delaware corporation (as successor by merger to CDRF Merger Sub, Inc., the "Borrower"), the Collateral Agent and the Lenders, the Lenders have severally agreed to make the Initial Term Loans and the Initial Revolving Loans (collectively, the "Loans") to the Borrower upon the terms and subject to the conditions set forth therein; and

WHEREAS, in connection with the First Lien Credit Agreement, the Grantor, Borrower, Holdings, and certain Domestic Subsidiaries of Borrower other than Grantor have executed and delivered a First Lien Guarantee and Collateral Agreement, dated as of the date hereof (as amended, supplemented or otherwise modified from time to time, the "First Lien Guarantee and Collateral Agreement"), in favor of the Collateral Agent; and

WHEREAS, pursuant to the First Lien Guarantee and Collateral Agreement, the Grantor granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all of its Intellectual Property, including the Patents; and

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and in order to induce the Lenders to make the Loans and other financial accommodations to the Borrower pursuant to the First Lien Credit Agreement, the Grantor agrees, for the benefit of the Secured Parties, as follows:

SECTION 1. <u>Confirmation of Grant of Security Interest</u>. The Grantor hereby confirms that, pursuant to the First Lien Guarantee and Collateral Agreement it granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all of the Patents of the Grantor

24044621v05

(including, without limitation, those items listed on <u>Schedule I</u> hereto) and to the extent not otherwise included, all Proceeds and products of any and all of the Patents, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Obligations of the Borrower, except that no security interest is or will be granted pursuant hereto in any right, title or interest of the Grantor under or in any Patent License for so long as, and to the extent that, the granting of such a security interest pursuant hereto would result in a breach, default or termination of such Patent License.

SECTION 2. <u>Purpose</u>. This Agreement has been executed and delivered by the Grantor for the purpose of recording the grant of security interest with the United States Patent and Trademark Office. This Agreement is expressly subject to the terms and conditions of the First Lien Guarantee and Collateral Agreement. The First Lien Guarantee and Collateral Agreement (and all rights and remedies of the Secured Parties thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 3. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with respect to the security interest in the Patents are more fully set forth in the First Lien Credit Agreement and the First Lien Guarantee and Collateral Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. In the event of a conflict between this Agreement and the First Lien Guarantee and Collateral Agreement, the provisions of the First Lien Guarantee and Collateral Agreement shall prevail.

SECTION 4. <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same instrument.

* * *

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

2

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first above written.

PHARMEDIUM SERVICES, LLC, as Grantor

By: PharMEDium Healthcare Corporation, its sole member

By: William R. Spalding

Title: Executive Vice President - Strategy,

Legal and Finance

JPMORGAN CHASE BANK, N.A., as Collateral Agent

13 ...

Name:

Dawn L. LeeLum

Title:

Executive Director

SCHEDULE I

PATENTS AND PATENT APPLICATIONS

Docket Number:	Application #:	Filing Date:	Title:	Patent #:	Issue Date:
P4252CIP	13/269,874	10-Oct-2011	OPERATING PHARMACEUTICAL IDENTIFICATION AND VERTIFICATION SAFETY	PENDING	PENDING
P4253US	13/443,600	10-Apr-2012	PHARMACEUTICAL IDENTIFICATION SAFETY DEVICE FOR SYRINGES	PENDING	PENDING
P4253CON	13/938,937	10-Jul-2013	PHARMACEUTICAL IDENTIFICATION SAFETY DEVICE FOR SYRINGES	PENDING	PENDING
P4254CON	13/926,759	25-Jun-2013	INTRAVENOUS BAG/LINE SAFETY DEVICE	8,597,271	03-Dec-2013
P4254CON	14/093,765	02-Dec-2013	INTRAVENOUS BAG/LINE SAFETY DEVICE	PENDING	PENDING
P4254US	13/743,981	17-Jan-2013	INTRAVENOUS BAG/LINE SAFETY DEVICE	PENDING	PENDING
P4255DES	29/411,083	17-Jan-2012	INTRAVENOUS BAG/LINE SAFETY DEVICE	D687,894	13-Aug-2013
P4274US	12/123,301	19-May-2008	SAFETY DEVICE FOR DRUG DELIVERY DEVICES AND CONTAINERS	7,918,830	05-Apr-2011
P4274CON	13/038,937	02-Mar-2011	SAFETY DEVICE FOR DRUG DELIVERY DEVICES AND CONTAINERS	8,382,717	26-Feb-2013
P4274CON	13/759,785	05-Feb-2013	SAFETY DEVICE FOR DRUG DELIVERY DEVICES AND CONTAINERS	PENDING	PENDING
P4279DES	29/298,328	03-Dec-2007	DRUG ADMINISTRATION SAFETY LABEL	D588,200	10-Mar-2009

24044621v05

Docket Number:	Application #:	Filing Date:	Title:	Patent #:	Issue Date:
,	29/332,180	10-Feb-2009	DRUG ADMINISTRATION SAFETY LABEL	D595,361	30-Jun-2009
DIV			ONLETT ENDEE		
P4279DES	29/332,179	10-Feb-2009	DRUG ADMINISTRATION SAFETY LABEL	D602,534	20-Oct-2009
DIV			SAFETT LABEL		
P4279DES	29/332,178	10-Feb-2009	DRUG ADMINISTRATION SAFETY LABEL	D593,613	02-Jun-2009
DIV			SAFETT LABEL		
P4279DES	29/343,304	10-Sep-2009	DRUG ADMINISTRATION SAFETY LABEL	D607,941	12-Jan-2010
DIV			SAPETT LABEL		
P4279DES	29/343,303	10-Sep-2009	DRUG ADMINISTRATION SAFETY LABEL	D614,703	27-Apr-2010
DIV			SAFELL LABEL		
P4279DES	29/343,301	10-Sep-2009	DRUG ADMINISTRATION	D605,230	01-Dec-2009
DIV			SAFETY LABEL		
P4279DES	29/343,298	10-Sep-2009	DRUG ADMINISTRATION	D605,229	01-Dec-2009
DIV			SAFETY LABEL		
P4279DES	29/343,297	10-Sep-2009	DRUG ADMINISTRATION	D605,228	01-Dec-2009
DIV			SAFETY LABEL		
P4281DES	29/318,375	19-May-2008	DRUG ADMINISTRATION	D597,608	04-Aug-2009
			SAFETY LABEL		
P4281DES	29/357,052	05-Mar-2010	DRUG ADMINISTRATION SAFETY LABEL	D624,595	28-Sep-2010
DIV			SAFELY LABEL		
P4281DES	29/357,060	05-Mar-2010	DRUG ADMINISTRATION	D621,880	17-Aug-2010
DIV			SAFETY LABEL		
P4281DES	29/357,063	05-Mar-2010	DRUG ADMINISTRATION	D624,596	28-Sep-2010
DIV			SAFETY LABEL		
P4281DES	29/357,056	05-Mar-2010	DRUG ADMINISTRATION	D621,879	17-Aug-2010
DIV			SAFETY LABEL		

Docket Number:	Application #:	Filing Date:	Title:	Patent #:	Issue Date:
,	29/357,069	05-Mar-2010	DRUG ADMINISTRATION SAFETY LABEL	D633,151	22-Feb-2011
DIV			O'METT EMBEL		
P4283DES	29/356,945	04-Mar-2010	DRUG ADMINISTRATION SAFETY LABEL	D634,368	15-Mar-2011
P4283DES DIV	29/384,768	03-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D639,862	14-Jun-2011
P4283DES DIV	29/384,771	03-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D639,863	14-Jun-2011
P4283DES DIV	29/384,767	03-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D639,861	14-Jun-2011
P4285DES	29/356,944	04-Mar-2010	DRUG ADMINISTRATION SAFETY LABEL	D634,367	15-Mar-2011
P4285DES DIV	29/384,866	04-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D641,421	12-Jul-2011
P4285DES DIV	29/384,869	04-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D643,468	16-Aug-2011
P4285DES DIV	29/384,879	04-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D641,422	12-Jul-2011
P4286DES	29/356,946	04-Mar-2010	DRUG ADMINISTRATION SAFETY LABEL	D634,369	15-Mar-2011
P4286DES DIV	29/384,979	07-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D645,094	13-Sep-2011
P4286DES DIV	29/384,981	07-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D643,469	16-Aug-2011
P4286DES DIV	29/384,983	07-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D643,470	16-Aug-2011

Docket Number:	Application #:	Filing Date:	Title:	Patent #:	Issue Date:
P4286DES DIV	29/384,986	07-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D649,196	22-Nov-2011
P4286DES DIV	29/384,987	07-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D643,471	16-Aug-2011
P4286DES DIV	29/384,989	07-Feb-2011	DRUG ADMINISTRATION SAFETY LABEL	D643,472	16-Aug-2011
P4311US	61/873,623	04-Sep-2013	IV BAG SHIELDING SYSTEM	PENDING	PENDING

24044621v05

RECORDED: 02/20/2014